Skip to content
preclinicalImmune & Inflammation

Substance P

Also known as: SP, Neurokinin A precursor, Tachykinin

Substance P is an 11-amino-acid neuropeptide (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂) of the tachykinin family that serves as a primary neurotransmitter for pain signaling, neurogenic inflammation, and mood regulation. Discovered in 1931, it was one of the first neuropeptides identified. Its receptor, neurokinin-1 (NK1R), is a major therapeutic target — NK1R antagonists like aprepitant are FDA-approved for chemotherapy-induced nausea, and the substance P/NK1R pathway is extensively researched for pain, depression, and inflammatory conditions.

4 cited references·5 researched benefits

Quick Answer

Substance P is an 11-amino-acid tachykinin neuropeptide that transmits pain signals from peripheral nerves to the spinal cord and brain. It binds the neurokinin-1 receptor (NK1R) to mediate pain perception, neurogenic inflammation, and stress responses. NK1R antagonists (like aprepitant for chemotherapy nausea) are FDA-approved drugs that block substance P signaling. Elevated substance P levels are associated with chronic pain, fibromyalgia, inflammatory bowel disease, and mood disorders.

Key Facts

Mechanism
Substance P is synthesized from preprotachykinin-A (PPT-A) gene products and stored in dense-core vesicles of C-fiber primary afferent neurons, enteric neurons, and central neurons. Released upon noxious stimulation, it binds the neurokinin-1 receptor (NK1R), a Gq-coupled GPCR that activates phospholipase C, increasing intracellular calcium and activating protein kinase C. In pain pathways, it transmits nociceptive signals from peripheral nerves to dorsal horn neurons. In inflammation, it causes vasodilation, plasma extravasation (neurogenic edema), and immune cell activation. Centrally, NK1R activation in the amygdala and hypothalamus modulates stress responses, anxiety, and emesis.
Research Status
preclinical
Half-Life
~1–2 minutes (rapidly degraded by neutral endopeptidase)
Molecular Formula
C₆₃H₉₈N₁₈O₁₃S
Primary Use
Immune & Inflammation
Table of Contents

Benefits

  • Pain signaling biomarker — substance P levels in cerebrospinal fluid serve as a biomarker for chronic pain conditions and treatment responsestrong
  • NK1R antagonist drug target — blocking substance P signaling has produced FDA-approved antiemetics (aprepitant, rolapitant)strong
  • Wound healing promotion — substance P promotes fibroblast proliferation and angiogenesis in skin woundsmoderate
  • Neurogenic inflammation research — understanding substance P drives development of anti-inflammatory therapies for asthma, IBD, and arthritismoderate
  • Mood disorder target — elevated substance P in depression and anxiety makes NK1R antagonism a potential antidepressant mechanismpreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Not administered therapeuticallyN/AN/ASubstance P is not used as a therapeutic agent due to its pro-inflammatory and pro-nociceptive effects. Clinical interest focuses on blocking its action using NK1R antagonists (aprepitant, fosaprepitant, rolapitant). Research applications use specific concentrations for in vitro and animal studies.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Pain sensitization — exogenous substance P increases pain sensitivity (hyperalgesia) through central sensitizationserious
  • Inflammation — promotes vasodilation, edema, and immune cell recruitment (neurogenic inflammation)common
  • Nausea/vomiting — substance P is a key mediator of the emetic reflex via NK1R activation in the area postremacommon
  • Bronchoconstriction — can trigger airway narrowing in susceptible individuals through neurogenic inflammationrare

Frequently Asked Questions

What role does substance P play in chronic pain?
Substance P is released from C-fiber nerve endings in the spinal dorsal horn, where it activates NK1R on secondary pain neurons, amplifying and prolonging pain signals — a process called central sensitization. In chronic pain conditions like fibromyalgia, substance P levels in cerebrospinal fluid are 2–3× higher than normal, correlating with pain severity. This sustained elevation contributes to the hyperalgesia (increased pain sensitivity) and allodynia (pain from normally non-painful stimuli) characteristic of chronic pain states.
How do NK1R antagonists like aprepitant work?
NK1R antagonists block substance P from binding its receptor, preventing downstream signaling. Aprepitant (Emend) is FDA-approved for chemotherapy-induced nausea and vomiting — it blocks NK1R in the area postrema and nucleus tractus solitarius, the brain regions controlling the vomit reflex. Clinical trials of NK1R antagonists for pain and depression have shown mixed results, suggesting substance P is one of many mediators in these complex conditions rather than the sole driver.
Is substance P involved in mental health conditions?
Elevated substance P levels have been found in the CSF and plasma of patients with major depression, PTSD, and anxiety disorders. The amygdala and hypothalamus express high levels of NK1R, and substance P modulates stress hormone release (CRH/ACTH/cortisol axis). Phase 2 clinical trials of NK1R antagonists showed antidepressant effects in some studies, but phase 3 trials failed to consistently outperform placebo. The field now views substance P as one component of stress neurobiology rather than a standalone treatment target.
What is the relationship between substance P and CGRP in migraines?
Both substance P and CGRP are released from trigeminal nerve fibers during migraine attacks, causing neurogenic inflammation in meningeal blood vessels. However, CGRP proved to be the more therapeutically tractable target — anti-CGRP antibodies (erenumab, fremanezumab, galcanezumab) and CGRP receptor antagonists (gepants) are now mainstay migraine preventives. NK1R antagonists showed less consistent efficacy for migraines, suggesting CGRP is the dominant mediator of trigeminovascular activation in this condition.
How was substance P discovered?
Substance P was first detected in 1931 by Ulf von Euler and John Gaddum, who found an unidentified substance in horse brain and intestinal extracts that contracted smooth muscle. They named it "Substance P" (for "Preparation" or "Powder"). Its amino acid sequence was determined in 1971 by Susan Leeman and Michael Chang. It was one of the first neuropeptides characterized, predating the discovery of endorphins, enkephalins, and most other neuropeptides by decades.

References

  1. 1
    Substance P and the neurokinin-1 receptor: the new CRH(2002)PubMed ↗
  2. 2
    Elevated cerebrospinal fluid substance P levels in fibromyalgia patients(1994)PubMed ↗
  3. 3
    NK1 receptor antagonists: a comprehensive review of their role in pain, inflammation, and psychiatric disorders(2009)PubMed ↗
  4. 4
    Tachykinins and their receptors: contributions to physiological and pathological processes(2014)PubMed ↗

Latest Research

Last updated: 2026-02-19